Time to Treatment Failure | ||
---|---|---|
Univariate Analysis | Multivariate Analysis | |
VARIABLE (Comparator) | HR (95% CI); p - value | HR (95% CI); p - value |
BMI ≥ 25 vs < 25 | 0.51 (0.44–0.60); p < 0.0001 | 0.67 (0.53–0.85); p = 0.0009 |
Weighta | 0.98 (0.97–0.99); p < 0.0001 | 0.99 (0.98–1.01); p = 0.8422 |
irAEs of any grade Yes vs No | 0.57 (0.48–0.66); p < 0.0001 | 0.79 (0.65–0.97); p = 0.0295 |
Primary Tumor (NSCLC) | ||
Melanoma Kidney Others | 0.62 (0.50–0.76); p < 0.0001 0.73 (0.59–0.92); p = 0.0077 1.15 (0.71–1.87); p = 0.5560 | 0.79 (0.64–1.01); p = 0.0517 0.71 (0.56–0.88); p = 0.0025 0.78 (0.48–1.28); p = 0.3389 |
Sex Male vs Female | 1.22 (1.04–1.43); p = 0.0147 | 1.10 (0.93–1.30); p = 0.2607 |
Age Elderly vs Non-elderly | 1.04 (0.90–1.21); p = 0.5366 | – |
Treatment line Non-first vs First | 1.36 (1.13–1.64); p = 0.0008 | 1.51 (1.25–1.81); p < 0.0001 |
N° of metastatic sites > 2 vs ≤ 2 | 1.54 (1.34–1.77); p < 0.0001 | 1.52 (1.30–1.77); p < 0.0001 |
ECOG PS ≥2 vs 0–1 | 2.86 (2.36–3.48); p < 0.0001 | 2.35 (1.92–2.88); p < 0.0001 |